Abstract
Introduction

Various pathologic stimuli have been shown to induce ventricular remodelling. These include myocardial infarction, chronic pressure overload (e.g. systemic arterial hypertension), chronic volume overload (e.g. valvular regurgitation), idiopathic dilated
cardiomyopathy and inflammatory heart muscle disease (e.g. myocarditis) [1] . In addition, growing evidence has shown that endothelin, angiotensin II (AngII) and tumour necrosis factor-␣ (TNF-␣) influence ventricular remodelling [2] . Elevated TNF-␣ levels have been reported to be directly related with functional heart failure [3] and TNF-␣ mRNA and protein have been shown to be uniformly expressed in failing human hearts [4] . [5] . Moreover, TNF-␣ transgenic mice, which generate cardiac-specific overexpression of TNF-␣, showed four-chamber dilatation, myocyte hypertrophy, extracellular matrix (ECM) remodelling with fibrosis and premature death with a 6-month mortality of 25% [6] . However, there is no published evidence showing the TNF-␣ can induce chronic ventricular remodelling. Moreover, the molecular mechanism might that mediate TNF-␣-induced cardiac remodelling is unclear. [7] . Many [8] . We previously reported that TNF-␣-induced oxidative stress in human aortic smooth muscle cells was mediated by increased activity of NADPH oxidase via upregulation of Nox4, but not Nox2 [9] . Another study reported that AngII-induced hypertrophic changes in rat vascular smooth muscle cells were mediated by upregulation of Nox4 [10] . Moreover, a recent study reported that human pulmonary artery smooth muscle cell proliferation induced by TGF-␤1 was mediated by upregulation of Nox4 [11] 
TNF-␣ infusion in a rat model revealed a time-dependent increase in left ventricular end-diastolic dimension compared to time-matched controls
Several mechanisms mediating cardiac and vascular remodelling have been suggested, including redox-sensitive signalling pathways. Despite the presence of many potential sources of reactive oxygen species (ROS), several studies have implicated NADPH oxidase as a major source of ROS
Materials and methods
Animals and experimental design
Male Swiss Albino mice (7) (8) [20] .
Immunohistochemistry
Alpha-smooth muscle actin (␣-SMA) expression in the ventricles was determined following the methods previously described with slight modification [14, 21] 
Cytokine assays
The concentrations of IL-1␤, IL-2, IL-6 and TNF-␣ were analysed in ventricular homogenates following procedures previously described [22] . Dissected 
Trolox equivalent antioxidant capacity (TEAC) assay
TEAC, an indicator of total antioxidant capacity of plasma was measured following the method previously described [23] . The assay relies on the ability of antioxidants in the plasma to inhibit the oxidation of 2,2Ј-Azinodi- [3- The glutathione assay was performed to determine the total glutathione GSH (GSH and GS-SG) using a Glutathione Assay Kit (Cayman Chemical Co., Ann Arbor, MI, USA) following the methods previously described [24] .
The kit uses an enzymatic recycling method using glutathione reductase to quantify glutathione (GSH). The sulfhydryl group of GSH reacts with 5,5Ј-dithio-bis-2-nitrobenzoic acid (DTNB) and produces a yellow coloured 5Ј-thio-2-nitrobenzoic acid (TNB). The mixed disulfide GSTNB is reduced by glutathione reductase to recycle the GSH and produce more TNB. Measurement of the absorbance of TNB at 405 nm provides an accurate estimation of GSH in the ventricular tissue.
Ventricular SOD activity was measured using a Superoxide Dismutase Assay Kit (Cayman Chemical Co.) following the methods previously described [25, 26] . The superoxide radical agents formed by the interaction of xanthine oxidase with hypoxanthine were detected by tetrazolium. One unit of SOD detected is equivalent to the amount of enzyme needed to exhibit 50% dismutase of superoxide radical.
NADPH oxidase activity assay
NADPH-dependent ROS production was measured in ventricular homogenates using 5 (and 6)-chloromethyl-2Ј, 7Ј-dichlorodihydrofluorescein diacetate-acetyl ester (CM-H2DCFDA; Molecular Probes) in 100 g
protein following the procedures previously described [13, 27] (Fig. 1A and B) (Fig. 1G) . Similar finding was observed in total GSH levels in the ventricles of TNF-␣-injected and control mice. Total GSH levels were slightly higher in those of TNF-␣-injected mice at all three time points compared to controls (Fig. 1H) . However, ventricular SOD levels show no difference among TNF-␣-injected and control mice (Fig. 1I ). (Fig. 2A) . However, no significant difference was observed between Nox2 mRNA levels of mice injected with TNF-␣ 7 and 28 days previously and control mice.
RNA extraction and real-time RT-PCR
Nox2 and Nox4 subunits are up-regulated in the ventricles of TNF-␣-treated mice
Analysis of Nox4 mRNA showed that it was different from the Nox2 mRNA expression profile. Nox4 mRNA levels were similar in mice injected with TNF-␣ 1 day previously and control mice (Fig. 2B) Fig. 2C and D) , whereas the protein levels of mice injected with TNF-␣ 7 and 28 days previously and control mice showed no significant differences. However, Nox4 protein expression of mice injected with TNF-␣ 7 and 28 days previously was significantly increased by 100% compared to controls (Fig. 2C and E) , whereas mice injected with TNF-␣ 1 day previously and control mice were similar.
Fluorescence intensities in the sections of TNF␣-injected mice were normalized with controls. Data were expressed as arbitrary fluorescence units (AFU) Ϯ S.D. (B). Mitochondrial ROS in the ventricular tissues were detected by incubating the sections with MitoSOX Red (5 M) for 10 min at 37ЊC. Representative of MitoSOX Red staining of ventricular tissues were shown (C) and normalized fluorescence intensities were shown (D). ROS in the ventricular homogenates was determined with CM-H2DCFDA. The fluorescence intensities of ventricular homogenates of TNF-␣-injected and control mice were shown (E). The source of ROS production in the ventricles of TNF-␣-injected mice was determined using different inhibitors. NADPH oxidase inhibitors (DPI and apocynin) significantly decreased ROS (F). Data were expressed as relative light unit (RLU) Ϯ S.D. SOD, superoxide dismutase; DPI, diphenyleneiodonium; L-NAME, N G -nitro-L-arginine methyl ester. Trolox equivalent antioxidant capacity (TEAC) assay was performed to detect capacity of antioxidants in the plasma and quantified as millimolar Trolox equivalent (G). Glutathione assay and superoxide dismutase assay were performed to determine the total GSH (H) and SOD levels (I) in the ventricles of TNF-␣-injected and control mice respectively. *P Ͻ 0.05.
Both Nox2 and Nox4 proteins were detected in all samples with the molecular weights identified in the manufacturer's protocol. Nox2 and Nox4 protein expression were similar to the mRNA profile. The Nox2 protein level of mice injected with TNF-␣ 1 day previously was significantly increased compared to controls (
Ventricular tissues of TNF-␣-treated mice are inflamed until 28 days post-injection
We measured IL-1␤, IL-2, IL-6 and TNF-␣ protein concentrations in ventricular tissue lysates. All four cytokines in mice injected with TNF-␣ were significantly elevated compared to controls until 28 days post-injection (Fig. 3). IL-1␤ concentrations of TNF-␣-injected mice were significantly elevated at 7 days post-injection compared to controls and more than 170% increased compared to TNF-␣-injected mice 1 day post-injection (Fig. 3A). IL-1␤ remained elevated until 28 days post-injection and was significantly higher than controls. Progressive elevation of IL-2 and IL-6 concentrations were observed in mice injected with TNF-␣ 7 and 28 days previously, whereas TNF-␣-injected mice 1 day post-injection
showed the same level compared to controls (Fig. 3B and C) . TNF-␣ protein concentrations in the ventricular tissue of TNF-␣-injected mice were significantly increased at all three time points (Fig. 3D) . These elevated levels of pro-inflammatory cytokines showed that ventricles of TNF-␣ injected mice are inflamed. (Fig. 4A) . The heart and body weight ratio (HW/BW) also increased in mice injected with TNF-␣ 7 and 28 days previously (Fig. 4B) . However, the significant difference was observed only mice 28 days post-injection.
Ventricular tissues of TNF-␣-treated mice underwent hypertrophy until 28 days post-injection
TNF-␣ injection into the mice resulted in hypertrophy of cardiomyocytes 7 and 28 days post-injection. The myocyte cross-sectional area showed a significant increase in mice injected with TNF-␣ 7 and 28 days previously compared to controls, while there was no significant change in myocyte area between day-1 treated and control mice
There was a significant increase in ANP gene expression at all three time points. Mice injected with TNF-␣ 1, 7 and 28 days previously showed a 1.5-, 9-and 4-fold increase, respectively, compared to controls (Fig. 4C) time points compared to controls (Fig. 4D) . ␣-SMA expressions detected by immunohistochemistry showed that the expression was increased in mice injected with TNF-␣ 7 and 28 days previously (Fig. 5) . However, the significant difference in ␣-SMA expression level was observed in the mice 28 days post-injection.
Ventricular dysfunction in TNF-␣-treated mice
Left ventricular cardiac function of all mice was evaluated in vivo with echocardiography (GE Vivid 7 with a linear 13 MHz probe). LVEDD was significantly increased 28 days post-injection, © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Upregulation of Nox2 and Nox4 mRNA and protein in ventricles of TNF-␣-injected mice. Total RNA was extracted from the ventricular tissues of TNF-␣-injected and control mice and Nox2 and Nox4 mRNA levels were examined using real-time PCR. Nox2 (A) and Nox4 mRNA levels (B) were shown. Nox2 and Nox4 protein levels were determined by immunoblotting. A representative of Nox2 and Nox4 proteins were shown (C). Densitometric analysis of Nox2 (D) and Nox4 protein (E) normalized with GAPDH were shown. C, control; T, TNF-␣-injected mice. *P Ͻ 0.05. whereas LVESD was significantly increased in mice injected with TNF-␣ 7 and 28 days post-injection compared to controls (Table 2). A significant decrease in the LVEF and FS was noted in mice injected with TNF-␣ 7 and 28 days previously compared to controls.
TNF-␣-induced IL-1␤ and IL-6 upregulation, and ROS production in adult human cardiomyotes is mediated by Nox2 and Nox4
Nox2 siRNA and Nox4 siRNA significantly decreased Nox2 and Nox4 mRNA levels by 45% and 80%, respectively, in adult human cardiomyocytes (Fig. 6A and B) . However, Nox2 and Nox4 siRNA showed no changes in Nox4 and Nox2 mRNA, respectively (data not shown). The role of Nox2 and Nox4 in TNF-␣-induced proinflammatory cytokine IL-1␤ and IL-6 expression, and ROS production was determined after knocking down Nox2 and Nox4. Nox2 siRNA significantly decreased TNF-␣-induced upregulation of IL-1␤ by 50% and IL-6 by 25% (Fig. 6C and D) . Nox4 siRNA also significantly decreased TNF-␣-induced upregulation of IL-1␤ by 45% and IL-6 by 30%. Nox2 and Nox4 siRNA had no effect on IL-1␤ and IL-6 expression without TNF-␣ treatment. Control siRNA had no effect on TNF-␣-induced upregulation of IL-1␤ and IL-6 (data not shown). Finally, Nox2 and Nox4 siRNA significantly decreased TNF-␣-induced ROS production by 40% and 50%, respectively (Fig. 6E) .
Discussion
The major finding of this study was that the pro-inflammatory cytokine TNF-␣-induced ventricular remodelling in mice up to 4 weeks after receiving a single dose, and this effect appeared to be regulated by NADPH oxidase-mediated ROS and upregulation of Nox2 and Nox4 subunits. Furthermore, Nox2 and Nox4 appeared to sequentially regulate the development of ventricular remodelling in mice (Nox2 for the short-term and Nox4 for the long-term development of ventricular remodelling). Another significant finding was TNF-␣-induced elevation of other proinflammatory cytokines (IL-1␤, IL-2 and IL-6) and TNF-␣ in the ventricles. Moreover, we confirmed that TNF-␣-induced ROS production and upregulation of IL-1␤ and IL-6 in human adult cardiomyocytes was mediated by the NADPH oxidase subunits Nox2 and Nox4.
Our findings are consistent with and extend published reports. Sun et al. [29] reported that excessive activation of TNF-␣ in the myocardium contributed to the development of chronic left ventricular dysfunction by inducing a local inflammatory response. Levine et al. [30] demonstrated elevated levels of TNF-␣ in patients with left ventricular dysfunction in the absence of clinical symptoms of heart failure, as well as patients with end-stage heart failure. Interestingly, Bozkurt et al. [5] [32] . The early phase of TNF-␣-induced myocardial depression occurs within minutes after TNF-␣ administration due to sphingosine production in the myocardium that leads to myocardial dysfunction and calcium dyshomeostasis in cardiomyocytes [33] . TNF-␣ administration, and is dependent upon expression of inducible nitric oxide synthase and an increase in the levels of nitric oxide, which leads to sustained contractile dysfunction [32, 34] . In this study, we reported a novel finding of TNF-␣-induced chronic myocardial dysfunction in mice that was characterized by ventricular dysfunctional changes on echocardiography in the presence of a slightly elevated antioxidant capacity in the plasma and total GSH levels in the ventricles. The molecular mechanism of TNF-␣-induced chronic inflammation needs to be elucidated, but other published work and our unpublished observations suggest that pericardial and perivascular adipose tissue act as endocrine organs and sources of chronic inflammation [35, 36] . [39] . The other possibility is that the heart acts as an endocrine organ and releases these cytokines [40] . This study convincingly showed that TNF-␣-induced upregulation of 
